175 related articles for article (PubMed ID: 20010481)
21. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
22. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
23. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
24. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
25. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Vispo E; Barreiro P; Pineda JA; Mira JA; Maida I; Martín-Carbonero L; Rodríguez-Nóvoa S; Santos I; López-Cortes LF; Merino D; Rivero A; Soriano V
Antivir Ther; 2008; 13(3):429-37. PubMed ID: 18572756
[TBL] [Abstract][Full Text] [Related]
26. Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.
Berzsenyi MD; Roberts SK
J Gastroenterol Hepatol; 2010 Apr; 25(4):655-6. PubMed ID: 20492322
[No Abstract] [Full Text] [Related]
27. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
[TBL] [Abstract][Full Text] [Related]
28. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
30. [Predictive value of virological response on sustained virological response in hepatitis C patients].
Zhou YQ; Wang XH; Fan Y; Zhu Y; Tan WT; Mao Q
Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):944-6. PubMed ID: 20038340
[No Abstract] [Full Text] [Related]
31. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies.
Ferenci P
J Antimicrob Chemother; 2004 Jan; 53(1):15-8. PubMed ID: 14645325
[TBL] [Abstract][Full Text] [Related]
32. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
[TBL] [Abstract][Full Text] [Related]
33. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
34. Chronic Hepatitis C Infection in Children.
Pham YH; Rosenthal P
Adv Pediatr; 2016 Aug; 63(1):173-94. PubMed ID: 27426900
[No Abstract] [Full Text] [Related]
35. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus: five-year follow-up of patients with sustained virological response.
Urquijo JJ; Diago M
Rev Esp Enferm Dig; 2011 Feb; 103(2):53-5. PubMed ID: 21366364
[No Abstract] [Full Text] [Related]
37. Role of statins in the treatment of chronic hepatitis C virus infection.
Abd-Eldaem AA; Azmy MK; Ahmad YK; Badr GA; Houssein MA; El-Dahshan T
J Egypt Soc Parasitol; 2012 Dec; 42(3):535-40. PubMed ID: 23469629
[TBL] [Abstract][Full Text] [Related]
38. Current and future treatment of hepatitis C.
Manns MP; Cornberg M; Wedemeyer H
Indian J Gastroenterol; 2001 Mar; 20 Suppl 1():C47-51. PubMed ID: 11293180
[TBL] [Abstract][Full Text] [Related]
39. [HCV entry as a new therapeutic target in chronic hepatitis C].
Dabrowska MM; Panasiuk A; Flisiak R
Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.
Shimakami T; Lanford RE; Lemon SM
Curr Opin Pharmacol; 2009 Oct; 9(5):537-44. PubMed ID: 19762279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
